Tango Therapeutics (TNGX) Corporate presentation summary

Strategic highlights and financial position

• Vopimetostat, a selective PRMT5 inhibitor, is positioned as first- and best-in-class with clinical validation and FDA support for a pivotal 2L pancreatic cancer study.

• Anticipated proof-of-concept data for RAS inhibitor combinations may establish vopimetostat as a foundational therapy for 1L pancreatic cancer.

• Multiple pipeline assets, including TNG456 and TNG961, target high-value indications such as glioblastoma and FOCAD-deleted cancers.

• $343M in cash as of December 31, 2025, provides runway into 2028, supporting accelerated clinical development.

Clinical development and efficacy data

• Vopimetostat shows a 27% ORR and 6.4-month mPFS across 16 tumor types, with strong tolerability and no discontinuations at 250mg QD.

• In 2L pancreatic cancer, vopimetostat achieved a 25% ORR and 7.2-month mPFS, more than double historical standards of care.

• In histology-selective cohorts, vopimetostat demonstrated a 49% ORR and 9.1-month mPFS, outperforming historical controls in multiple indications.

• Early combination studies with RAS inhibitors show encouraging efficacy and safety, with pivotal 1L pancreatic cancer studies planned.

Pipeline and innovation

• TNG456, a CNS-penetrant PRMT5 inhibitor, is in phase 1/2 trials for glioblastoma, with FDA Fast Track and Orphan Drug designations.

• TNG260 targets COREST in STK11-mutant cancers, restoring PD-1 responsiveness in preclinical models and showing early clinical proof-of-concept.

• TNG961, an HBS1L degrader, targets FOCAD-deleted cancers and has shown potent, selective tumor regression in preclinical models.